SCHEMBL1601403

SCHEMBL1601403

CC(C)(C)[Si](C)(C)OCc1cc(C(F)(F)F)ccc1C(O)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 4/20 0.46
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
CFTR P13569 3/20 0.33
EPHX1 P07099 4/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
ADRB2 P07550 1/20 0.33
IDO1 P14902 1/20 0.32
TACR1 P25103 1/20 0.32
PSMB11 A5LHX3 1/20 0.32
PSMA7 O14818 1/20 0.32
PSMB1 P20618 1/20 0.32
PSMA1 P25786 1/20 0.32
PSMA2 P25787 1/20 0.32
PSMA3 P25788 1/20 0.32
PSMA4 P25789 1/20 0.32
PSMB8 P28062 1/20 0.32
PSMB9 P28065 1/20 0.32
PSMA5 P28066 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1600937 1.00 PDE2A (0.46) PDE2ACYP1A2CYP2D6CYP2C19CFTR
SCHEMBL1600845 0.99 PDE2A (0.47) PDE2ACYP1A2CYP2D6CYP2C19CFTR
SCHEMBL1600352 0.86 PDE2A (0.33) PDE2ACYP1A2CYP2D6CYP2C19CFTR
SCHEMBL1600354 0.86 PDE2A (0.33) PDE2ACYP1A2CYP2D6CYP2C19CFTR
SCHEMBL1599639 0.85 PDE2A (0.33) PDE2ACFTREPHX1IDO1TACR1
SCHEMBL1601213 0.80 PDE2A (0.33) PDE2ACYP2C19ADRB2IDO1TACR1
SCHEMBL3954842 0.77 CYP2D6 (0.36) CYP1A2CYP2D6CYP2C19CFTRPTGDR2
SCHEMBL1601508 0.76 CFTR (0.40) CFTRPTGDR2TACR1KMT2A
SCHEMBL4609571 0.75 BACE1 (0.40) PDE2ACYP2D6ADRB2TACR1
SCHEMBL4609574 0.75 BACE1 (0.40) PDE2ACYP2D6ADRB2TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919506-B2 Dibenzyl amine compounds and derivatives PFIZER INC. (US) 2011-04-05 US disclosed
US-7919506-B2 Dibenzyl amine compounds and derivatives PFIZER INC. (US) 2011-04-05 US disclosed
EP-1996564-A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES Pfizer Products Incorporated (US) 2008-12-03 EP disclosed
WO-2007105050-A1 DIBENZYL AMINE COMPOUNDS AND DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-09-20 WO disclosed
US-20070213371-A1 Dibenzyl Amine Compounds and Derivatives PFIZER INC 2007-09-13 US disclosed
US-20070213371-A1 Dibenzyl Amine Compounds and Derivatives PFIZER INC 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213371-A1 Dibenzyl Amine Compounds and Derivatives APOB, LDLR, CETP PDE2A 404/4885CYP1A2 548/4885CYP2D6 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.